Rituximab for anti-vimentin antibody disease
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests if rituximab, a targeted immune therapy, can help people with a newly identified antibody-linked condition. You may qualify if you have positive anti-vimentin antibodies in spinal fluid and signs of active disease such as new MRI lesions or worsening symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have anti-vimentin antibodies in your spinal fluid
- You must have an EDSS score of 3.5 or higher, or signs of recent disease activity like new MRI lesions or symptom worsening within the last 6 months
- You cannot have active infections, certain heart conditions, or recent serious health events
- You cannot have a history of certain cancers in the last 5 years
- Women who can become pregnant must use reliable birth control and not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
This Phase 3 study tests rituximab, an immune-focused medicine, for people with a first episode or relapse of psychosis who have specific brain-targeting autoantibodies in their blood. It may help calm symptoms by changing how the immune system contributes to the illness.
This trial tests if rituximab can help treat moderate to severe side effects caused by immunotherapy (checkpoint inhibitors) in people with melanoma. If you have had immunotherapy for melanoma in the last 3 months and are now dealing with troublesome side effects, this study may offer a way to manage them.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Anti-Vimentin Antibody-associated Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.